SG11201707683YA - C/ebp alpha sarna compositions and methods of use - Google Patents

C/ebp alpha sarna compositions and methods of use

Info

Publication number
SG11201707683YA
SG11201707683YA SG11201707683YA SG11201707683YA SG11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA
Authority
SG
Singapore
Prior art keywords
methods
ebp alpha
sarna compositions
compositions
alpha sarna
Prior art date
Application number
SG11201707683YA
Other languages
English (en)
Inventor
Andreas Wagner
Robert Habib
Hans E Huber
Pål Saetrom
Endre Bakken Stovner
Markus Hossbach
Monika Krampert
Hans-Peter Vornlocher
Original Assignee
Mina Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mina Therapeutics Ltd filed Critical Mina Therapeutics Ltd
Publication of SG11201707683YA publication Critical patent/SG11201707683YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/352Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521Methyl
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/353Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533Halogen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201707683YA 2015-04-22 2016-04-21 C/ebp alpha sarna compositions and methods of use SG11201707683YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562150889P 2015-04-22 2015-04-22
US201562235778P 2015-10-01 2015-10-01
US201662308521P 2016-03-15 2016-03-15
PCT/GB2016/051117 WO2016170349A1 (en) 2015-04-22 2016-04-21 C/ebp alpha sarna compositions and methods of use

Publications (1)

Publication Number Publication Date
SG11201707683YA true SG11201707683YA (en) 2017-11-29

Family

ID=55948895

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201707683YA SG11201707683YA (en) 2015-04-22 2016-04-21 C/ebp alpha sarna compositions and methods of use

Country Status (8)

Country Link
US (2) US10912790B2 (cg-RX-API-DMAC7.html)
EP (1) EP3286316A1 (cg-RX-API-DMAC7.html)
JP (4) JP6768701B2 (cg-RX-API-DMAC7.html)
KR (2) KR102599712B1 (cg-RX-API-DMAC7.html)
CN (2) CN114525279A (cg-RX-API-DMAC7.html)
AU (3) AU2016251415B9 (cg-RX-API-DMAC7.html)
SG (1) SG11201707683YA (cg-RX-API-DMAC7.html)
WO (1) WO2016170349A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3071696B1 (en) * 2013-11-22 2019-08-07 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
WO2018104538A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
EP3679140B1 (en) * 2017-09-08 2022-11-16 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
EP3679139B1 (en) 2017-09-08 2022-11-02 MiNA Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
CN108103108A (zh) * 2018-01-30 2018-06-01 上海交通大学医学院附属瑞金医院 Cebpa基因缺失斑马鱼突变体的制备及其应用
WO2019158720A1 (en) 2018-02-16 2019-08-22 Mina Therapeutics Limited C/ebp alpha sarna compositions and methods of use
JP7432521B2 (ja) * 2018-04-10 2024-02-16 ラクティゲン セラピューティクス 新規小分子活性化rna
CN112543809A (zh) * 2018-06-15 2021-03-23 米纳治疗有限公司 包含C/EBPα saRNA的组合疗法
EP4003423A4 (en) * 2019-07-26 2024-03-06 MiNA Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
WO2021021744A1 (en) * 2019-07-29 2021-02-04 Lee Chae Method for improving digestive health
WO2021052470A1 (zh) * 2019-09-20 2021-03-25 中美瑞康核酸技术(南通)研究院有限公司 用于治疗血小板减少症的核酸分子及其应用
WO2021113158A1 (en) * 2019-12-03 2021-06-10 Merck Sharp & Dohme Corp. In vitro cell based potency assay
GB202019692D0 (en) * 2020-12-14 2021-01-27 Apterna Ltd Aptamer-sirna fusions
WO2022147044A1 (en) 2020-12-28 2022-07-07 Gjerde Doulas T Temperature stable nucleic acid method for preparing vaccine
WO2022166814A1 (zh) * 2021-02-07 2022-08-11 中美瑞康核酸技术(南通)研究院有限公司 一种化学修饰的小激活rna
EP4329777A1 (en) 2021-04-28 2024-03-06 MiNA Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
KR102428121B1 (ko) * 2021-10-20 2022-08-08 주식회사 네오나 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료를 위한 딜리버리 시스템
CN114306367B (zh) * 2021-08-27 2023-03-28 赵小洋 一种含有C/EBPα-saRNA的组合物
EP4633618A1 (en) * 2022-12-12 2025-10-22 Regeneron Pharmaceuticals, Inc. Treatment of type 2 diabetes and/or chronic kidney disease with hepatocyte nuclear factor 4 alpha (hnf4a) agonists
WO2024134199A1 (en) * 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2024165876A2 (en) * 2023-02-10 2024-08-15 Mina Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
WO2024175887A1 (en) 2023-02-22 2024-08-29 Mina Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
KR20240138691A (ko) * 2023-03-13 2024-09-20 부산대학교 산학협력단 류마티스 관절염 진단용 바이오마커 조성물, 이를 이용한 진단용 키트 및 이를 이용한 류마티스 관절염 진단방법
WO2025007024A1 (en) * 2023-06-29 2025-01-02 Repertoire Immune Medicines, Inc. Lipid particles for delivering a payload
WO2025052098A1 (en) 2023-09-08 2025-03-13 Mina Therapeutics Limited Tmem173 sarna compositions and methods of use
CN118480552B (zh) * 2024-01-18 2024-10-01 成都先衍生物技术有限公司 一种靶向CEBPA基因表达的saRNA及其用途
WO2025224036A1 (en) * 2024-04-22 2025-10-30 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582744B2 (en) * 2004-08-10 2009-09-01 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
WO2010055147A1 (en) * 2008-11-13 2010-05-20 Erasmus University Medical Center Rotterdam Efficient detection of double mutants of the cebpa gene in acute myeloid leukemia
ES2629339T3 (es) * 2009-06-16 2017-08-08 Curna, Inc. Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
GB201010557D0 (en) * 2010-06-23 2010-08-11 Mina Therapeutics Ltd RNA molecules and uses thereof
CA2817256A1 (en) * 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
EP4060043A1 (en) * 2011-06-21 2022-09-21 MiNA Therapeutics Limited Albumin production and cell proliferation
DE102011079572B4 (de) * 2011-07-21 2024-12-05 Endress+Hauser Conducta Gmbh+Co. Kg Gradiometer zur Bestimmung der elektrischen Leitfähigkeit eines in einem Behältnis enthaltenen Mediums
BR112015010220A2 (pt) * 2012-11-05 2017-12-05 Pronai Therapeutics Inc métodos de utilização de biomarcadores para tratamento de câncer
BR112015010106A2 (pt) * 2012-11-05 2017-08-22 Pronai Therapeutics Inc Dosagem e administração de terapias para câncer com oligonucleotídeo
US20150299804A1 (en) * 2012-11-15 2015-10-22 Bristol-Myers Squibb Company Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
EP3071696B1 (en) * 2013-11-22 2019-08-07 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
JP7073109B2 (ja) * 2015-07-02 2022-05-23 シティ・オブ・ホープ ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法

Also Published As

Publication number Publication date
JP6768701B2 (ja) 2020-10-14
US10912790B2 (en) 2021-02-09
JP6931733B2 (ja) 2021-09-08
WO2016170349A1 (en) 2016-10-27
JP2021000119A (ja) 2021-01-07
AU2019210578A1 (en) 2019-08-22
KR102760315B1 (ko) 2025-02-04
JP2024079713A (ja) 2024-06-11
AU2019210578B2 (en) 2022-01-13
JP2021192616A (ja) 2021-12-23
EP3286316A1 (en) 2018-02-28
KR20170136542A (ko) 2017-12-11
US20210187007A1 (en) 2021-06-24
KR20230156961A (ko) 2023-11-15
US20200376020A1 (en) 2020-12-03
CA2980975A1 (en) 2016-10-27
AU2016251415B9 (en) 2019-05-23
KR102599712B1 (ko) 2023-11-09
JP2018516545A (ja) 2018-06-28
AU2016251415B2 (en) 2019-05-02
CN108291228A (zh) 2018-07-17
AU2022202355A1 (en) 2022-04-28
AU2016251415A1 (en) 2017-10-12
CN114525279A (zh) 2022-05-24

Similar Documents

Publication Publication Date Title
SG11201707683YA (en) C/ebp alpha sarna compositions and methods of use
IL274276A (en) CASZ preparations and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
ZA201707981B (en) Compositions of obeticholic acid and methods of use
ZA201801511B (en) Flavonoid compositions and methods of use
IL257307B (en) Transgenic crispr–cas9 preparations and methods of use
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
PT3352766T (pt) Composições de hialuronano de elevada elasticidade e processos para o seu uso
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
ZA201906169B (en) Synthekine compositions and methods of use
PL3349743T3 (pl) Sposoby i kompozycje do hamowania oddziaływania dcn1-ubc12
HUE057883T2 (hu) Peptid készítmények és felhasználási módszerek
EP3190886A4 (en) Compositions and methods of use thereof
IL265761A (en) Terlipressin compounds and methods of using them
IL256843B (en) Cleaning products and methods of using them
GB2600888B (en) Magnesium biotinate compositions and methods of use
SG11201803284YA (en) Novel method of use and compositions
GB201511799D0 (en) Composition and methods of treatment
IL246711A0 (en) Biologically active haloperoxidase compositions and methods of using them
EP3253396A4 (en) Probiotic compositions and methods of use
EP3207029A4 (en) Tryptamide compositions and methods of use
IL261794A (en) Preparations and methods for using them
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
ZA201606358B (en) Compositions of selenoorganic compounds and methods and methods of use thereof